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visiting psychiatrists. The issues of over-medication and polypsy-
chopharmacy deserve further attention.
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OBJECTIVES: Up to 75% of patients with bipolar disorder
report at least one lifetime hospitalization; patients treated with
second generation antipsychotics (SGAs) and mood stabilizers
(MS) are hospitalized more frequently than those treated with
MS monotherapy. It is not clear whether different SGAs differ-
entially reduce the risk of hospitalization in this at-risk popu-
lation, therefore the purpose of this study is to characterize
hospitalization rates in patients treated with adjunctive
SGA-MS combination therapy. METHODS: A retrospective
propensity score-matched cohort study was conducted in the
LabRx integrated claims database from January 2003 through
December 2006. Patients 18–65 with bipolar disorder and 180
days of pre-index enrollment without SGA therapy and 90 days
post-index enrollment were eligible for inclusion. MS therapy
was initiated within 30 days prior to or following index SGA
prescription. Multivariate logistic regression was used to esti-
mate the risk of hospitalization in patients treated with arip-
iprazole, olanzapine, quetiapine, risperidone, or ziprasidone
during the 90 day follow-up period. RESULTS: Of 7134
patients meeting inclusion criteria, 920 patients on aripiprazole
were matched to 920 on olanzapine, quetiapine, or risperidone,
while 518 aripiprazole patients were matched to 518 on
ziprasidone. Hospitalization rates in the ﬁrst 90 days following
index prescription was 9.3% (range 7.1–12.8%). Compared to
aripiprazole, patients on adjunctive SGAs demonstrated statis-
tically signiﬁcantly greater risks of hospitalization (olanzapine
OR 1.8, 95%CI 1.3, 2.7; quetiapine OR 1.5, 95%CI 1.1, 2.2;
risperidone OR 1.8, 95%CI 1.3, 2.6; ziprasidone OR 1.7,
95%CI 1.1, 2.7). CONCLUSIONS: Hospitalization in the ﬁrst
90 days following initiation of combination mood stabilizer-
SGA therapy is relatively common and inﬂuenced by choice of
SGA. This difference may be due to dosing and titration under
real world conditions.
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OBJECTIVES: Empirical studies show a severe undertreatment
of patients with Alzheimer’s disease in Germany. This compara-
tive online panel survey investigates potential causes for under-
treatment among general practitioners (GPs) and neurologists/
psychiatrists. METHODS: A total of 100 neurologists/
psychiatrists and 302 GPs were included in an online panel
survey. Participating GPs had experiences in treating diabetes,
asthma, depression, epilepsy, migraine and dementia; neurolo-
gists were experienced in schizophrenia, depression, epilepsy,
multiple sclerosis, migraine and dementia. Participants were
asked to compare these therapeutic areas in 8 items: urgency of
treatment, therapeutic options, difﬁculties in diagnosis, knowl-
edge on guidelines, difﬁculties in patient and care-giver commu-
nication, inﬂuence of budget restrictions, experiences in
switching therapy and referrals to specialists. A Likert-rating
scale (1–5) was used for assessing. An additional open question
addressed reasons for discontinuing therapy with antidementive
drugs. RESULTS: For Alzheimer’s disease GPs see lowest
urgency for treatment (2.2; 1.3 in diabetes), lowest number of
therapeutic options (3.5; 1.5 in asthma), largest difﬁculties in
diagnosis (3.3; 1.7 in diabetes), largest difﬁculties in patient and
care-giver communication (3.7; 1.9 in diabetes) and highest
budget restrictions (2.0; 2.8 in epilepsy). GPs’ knowledge of
guidelines is lowest in epilepsy (3.4) and dementia (3.0; 1.7 in
diabetes); their experience in therapeutic switches is lowest, the
number of referrals to specialists highest. Neurologists agree
with GPs that therapeutic options in dementia are lowest (3.5,
1.5 in schizophrenia) and budget pressure is highest (1.9; 2.7 in
epilepsy). They see a higher urgency of treatment for Alzheimer
and show more experience in treatment. Both groups agreed
that budget restraints are the most important reason for discon-
tinuing treatment with antidementive drugs. CONCLUSIONS:
Results suggest that budget constraints for GPs and
neurologists/psychiatrists are the dominant reason for under-
treatment of patients with Alzheimer’s disease. To ensure
evidence-based treatment with antidementive drugs in Germany
budget constraints need to be reduced.
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OBJECTIVES: Controlling pharmaceutical expenditures is of
particular interest to governments, as pharmaceuticals present
one of the main components of health care expenditures. Patent
expiries of drugs are important, as dispensing (cheaper) generic
drugs potentially results in lower pharmaceutical expenditures.
Therefore, modelling generic substitution patterns is highly rel-
evant as this can provide useful cost-cutting decision support.
The aim of this study was to model the duration until patients
switch from branded to generic drugs, in relation to various
inﬂuencing variables METHODS: Data were obtained from
Dutch pharmacy dispensing records from IADB.nl. We focused
on antidepressant prescription data. To identify a pattern on the
underlying diffusion process, the analysis was applied to four
antidepressants whose patent recently expired (ﬂuoxetine, par-
oxetine, citalopram, sertraline). Duration analysis techniques
were used to estimate the probability of patients to switch to a
generic drug over time, and to estimate the effect of different
covariates (e.g. patient, pharmacist and general practitioner char-
acteristics) on this switching probability. Since interval censored
data were used, discrete duration methods were applied which
resulted in the estimation of a binary regression model.
RESULTS: A higher probability for patients to switch from a
branded to a generic drug within the ﬁrst ﬁve months after patent
expiry was identiﬁed. Switching probabilities were mainly
affected by the general practitioners’ and pharmacists’ inclination
to provide generic drugs, the age, the experience of the patient on
the speciﬁc drug and the amount of different generic drugs intro-
duced in the market. CONCLUSIONS: Despite differences in
pharmacy dispensing patterns for different antidepressants
studied, we generally found common patterns in generic substi-
tution. Next to the inclination of health care professionals,
patient characteristics, time and the amount of available generic
alternatives affect generic substitution signiﬁcantly. However,
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